Latest Upcoming Webinars

Combining both real-time live-cell imaging with biosensor-based impedance measurements is now possible for the first time, providing a multi-parametric, information-rich cellular analysis.

In this webinar, Dr. Holz will discuss the background of cell-to-cell communication, highlighting studies and recent developments in the field as well as exploring the clinical implications of these studies on cancer biology and patient care.

Since the dawn of domestication, humans have been shaping the traits of animals for the benefit of society by way of selective breeding.

Do you want to bring your CAR T-cell research into clinical applications?

Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR T-cell therapies – from basic research to process development and clinical manufacturing. Discover the products, tools and services that build on Miltenyi Biotec’s expertise to move your CAR T-cell projects forward.

Attend this webinar to learn about:
- Discover opportunities that exist in clinical research testing for protein biomarkers (particularly in cardiovascular disease)
- Learn the advantages in performing protein quantification at higher flow rates
- Understand the considerations for implementing an LC-MS analysis for protein biomarker quantification in a clinical translational context

Do you want to bring your CAR NK cell and Treg cell research into clinical applications?

Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR NK cell and Treg-based therapies – from basic research to process development and clinical manufacturing. Discover the products, tools and services that build on Miltenyi Biotec’s expertise to move your CAR NK and Treg projects forward.

This webinar explores the use of high-resolution ion mobility performed on the MOBIE platform for the characterization of different lipid classes starting from phosphatidylcholines and gangliosides.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.

Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.

Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?

In this webinar, we will explore the common challenges encountered by developers and manufacturers when developing PCR tests, and how these challenges can be overcome with the right technologies.

In this webinar, get up to date with the new standards and explore how the SpeedCal Mobile and Cubis® II product solutions from Sartorius can help to set up a future-proof working environment for your lab.